Levels of the IGF system components in malignant lesions of the lungs with preventive effect of 1,3-diethylbenzimidazolium triiodide in the experiment

Background. The system of insulin-like growth factors (IGF) is involved in carcinogenesis. Objective. Studying the dynamics of the IGF system components in the lungs of rats with antitumor effect of 1,3-diethylbenzimidazolium triiodide (Stellanin). Design and methods. The main group included male (n = 27) and female (n = 27) white outbred rats with sarcoma 45 (s45) inoculated into the subclavian vein but not developed in the lungs (2 × 10⁶ cells) due to Stellanin administration (intragastrically, 0.4 mg/kg once a day according to the regimen: administration for 5 days with a 2-day interval). Control group included males (n = 14) and females (n = 14) with s45 growing in the lungs without treatment. Levels of IGFI-II and IGFBP1-3 were measured by ELISA in 10 % lung homogenates obtained at weeks 4–8. Results. The s45 development in the lung was accompanied by the IGF-I increase by 2.4–3.0 times in males and by 4.3 times in females, and the opposite IGF-II dynamics: an increase in males (by 4.6 times) and decrease in females (by 4.3 times), together with the IGFBP decline. Stellanin upregulated IGF-I levels in the lungs of all rats on average by 1.3 times (p < 0.05) and normalized IGF-II in males, while increasing it in females by 1.6 times (p < 0.05), together with higher (compared to controls) IGFBP levels. Conclusion. Preventive anticancer effect of Stellanin is based on the stabilization of the IGF system grossly altered during the malignant process development in the lung.

carcinogenesis, IGF, IGFBP, lung tumor, organic iodine, rats, Stellanin

1. Cevenini A, Orrù S, Mancini A, et al. Molecular signatures of the insulin-like growth factor 1-mediated epithelial-mesenchymal transition in breast, lung and gastric cancers. Int J Mol Sci. 2018; 19 (8): 2411.

2. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15 (3): 178–196.

3. Li H, Batth IS, Qu X, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017; 16 (1): 6.

4. Sato Y, Inokuchi M, Takagi Y, et al. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer. J Clin Pathol. 2015; 68 (10): 795–801.

5. Chen YM, Qi S, Perrino S, et al. Targeting the IGFaxis for cancer therapy: development and validation of an IGF-trap as a potential drug. Cells. 2020; 9 (5): 1098.

6. Brouwer-Visser J, Huang GS. IGF2 signaling and regulation in cancer. Cytokine Growth Factor Rev. 2015; 26 (3): 371–377.

7. Vishwamitra D, George SK, Shi P, et al. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 2017; 8 (1): 1814–1844.

8. Imperlini E, Mancini A, Alfieri A, et al. Molecular effects of supraphysiological doses of doping agents on health. Mol Biosyst. 2015; 11 (6): 1494–1506.

9. Nishida Y, Matsubara T, Tobina T, et al. Effect of low-intensity aerobic exercise on insulin-like growth factor-I and insulin-like growth factor-binding proteins in healthy men. Int J Endocrinol. 2010; 2010: 452820.

10. Sidorenko YuS, Frantsiyants EM, Tkalya LD. Method for simulation of malignant process in experiment. Patent on the application #2008133088, 11.08.2008. In Russian

11. Shikhlyarova AI, Frantsiyants EM, Nepomnyashchaya EM, et al. Characteristics of structural changes in the lungs of male and female rats with intravenous inoculation of sarcoma-45. Voprosy onkologii=Oncology issues. 2010; 56 (5): 632–637. In Russian

12. Kit OI, Franciyanc EM, Dimiriadi SN, et al. Neoangiogenesis and fibrinolytic system biomarkers expression in the dynamics of experimental kidney ischemia in rats. Eksperimental’naya i klinicheskaya urologiya=Experimental and clinical urology. 2015; 1: 20–23. In Russian

13. Frantsiyants EM, Kaplieva IV, Trepitaki LK, et al. Method of lung metastasis prevention in experiment. Experimental and Clinical Pharmacology. 2018; 81(10): 24–28. In Russian

14. Cai Q, Dozmorov M, Oh Y. IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer. Cells. 2020; 9 (5): 1261.

15. Wang J, Hu Z-G, Li D, et al. Gene expression and prognosis of insulinlike growth factorbinding protein family members in nonsmall cell lung cancer. Oncol Rep. 2019; 42 (5): 1981–1995.

16. Hu Q, Zhou Y, Ying K, et al. IGFBP, a novel target of lung cancer? Clin Chim Acta. 2017; 466: 172–177.

17. Cao Y, Nimptsch K, Shui IM, et al. Prediagnostic plasma IGFBP-1, IGF-I and risk of prostate cancer. Int J Cancer. 2015; 136 (10): 2418–2426.

18. Tas F, Bilgin E, Tastekin D, et al. Serum IGF-I and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomed Rep. 2016; 4 (5): 609–614.

19. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014; 14 (5): 329–341.

20. Yazawa T, Sato H, Shimoyamada H, et al. Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol. 2009; 175 (3): 976–987.

21. Alami N, Page V, Yu Q, et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res. 2008; 18 (6): 487–496.

22. Kim J-H, Choi DS, Lee OH, et al. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGFindependent suppression of Erk1/2 activation and Egr1-mediated transcriptional events. Blood. 2011; 118 (9): 2622–2631.

23. Fürstenberger G, Senn H-J. Insulin-like growth factors and cancer. Lancet Oncol. 2002; 3 (5): 298–302.

24. Wang YA, Sun Y, Palmer J, et al. IGFBP3 modulates lung tumorigenesis and cell growth through IGF1 signaling. Mol Cancer Res. 2017; 15 (7): 896–904.